Serum Maresin-1 Predicts the Severity of Severe Acute Pancreatitis

Serum Maresin-1 Level Predicts the Disease Severity and Clinical Outcomes of Severe Acute Pancreatitis Patients

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT03364920

Enrollment

200

Registered

2017-12-07

Start date

2018-01-01

Completion date

2020-01-01

Last updated

2017-12-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pancreatitis, Acute

Keywords

Maresin-1, SAP, IPN, MODS, Mortality

Brief summary

This is a retrospective study about serum Maresin-1 level in different severe acute pancreatitis patients. The investigators want to study the correlation between the level of serum Maresin-1 and the severity of SAP, of course the clinical outcomes. The investigators want to find some biomarkers and strategy target drugs of severe acute pancreatitis.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 75 Years

Healthy volunteers

Yes

Inclusion criteria

* Clinical diagnosis of Severe Acute Pancreatitis * Biliary pancreatitis * 7 days of the onset

Exclusion criteria

* Surgical patients * Serious diseases and infection * Alcoholic pancreatitis * Hypertriglyceridemia pancreatitis * Disorder of Glucolipide Metabolism：diabetes mellitus, hypertriglyceridemia, BMI\>30

Design outcomes

Primary

Measure	Time frame	Description
mortality	up to 28 days	The level of serum maresin-1 predicts the severity of severe acute pancreatitis

Secondary

Measure	Time frame	Description
The incidence of MODS	through study completion, an average of 1 year	The level of serum maresin-1 predicts the severity of severe acute pancreatitis
The incidence of IPN	through study completion, an average of 1 year	The level of serum maresin-1 predicts the severity of severe acute pancreatitis

Contacts

Primary ContactWeiqin Li

luyingying126@sina.cn13962531994

Outcome results